To access the relationship between metabolic control of children and adolescents with type 1 diabetes and cardiometabolic risk through noninvasive imaging modalities to assess the early vasculature changes.

Inclusion Criteria:

• Type 1 diabetes for more than 0.5 year
• Age ≥ 10 years up to 25 years (inclusive)
• The subject/carer is willing to follow study specific instructions

Exclusion Criteria:

• Youth with maturity-onset diabetes of the young, hybrid, other, or missing type
• Any significant diseases / conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study
• Current use of the following medications: medications that are used to lower blood glucose such as Pramlintide, Metformin and GLP-1 analogs. Beta blockers, glucocorticoids and other medications, which in the judgment of the investigator would be a contraindication to participation in the study (Anticoagulant therapy e.g. Plavix, LMW heparin, Coumadin, Immunosuppressant therapy)

Nationwide cohort of children and adolescents with type 1 diabetes